Medindia
Medindia LOGIN REGISTER
Advertisement

IRIDEX Announces First Quarter 2010 Conference Call and Release Date

Thursday, April 29, 2010 General News
Advertisement


MOUNTAIN VIEW, Calif., April 29 IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its first quarter 2010 financial results after the market closes on Thursday, May 6, 2010. In conjunction with the release, the Company will host a conference call with the investment community at 5:00 p.m. Eastern Time on Thursday, May 6, 2010 to discuss the results of the quarter and other business developments.
Advertisement

Interested parties may access the live conference call via telephone by dialing (888) 549-7880 U.S. or (480) 629-9867 (International) and quoting Conference ID 4291498, or by visiting the Company's website at www.iridex.com. A telephone replay will be available beginning on Thursday, May 6, 2010 through Thursday, May 13, 2010 by dialing (800) 406-7325 (US) or (303) 590-3030 (International) and entering Access Code 4291498.
Advertisement

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com.

SOURCE IRIDEX Corporation
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close